Trial Profile
Ixekizumab in the Treatment of Bullous Pemphigoid
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Bullous pemphigoid
- Focus Therapeutic Use
- 15 Aug 2019 Status changed from recruiting to completed.
- 11 Dec 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 11 Dec 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Jul 2019.